menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
PeterLassoff
Even the largest biopharmaceutical companies today shy away from maintaining massive global infrastructures to manage every single aspect of their operations. The move toward more agile,  partner-driven models has enabled them to cut costs, gain efficiencies and reduce their risks by taking advantage of the existing skills and infrastructure of other industry experts.  But there are still avenues to follow that can further add agility and productivity to their processes. The key is identifying tactical operational work that is necessary but does not drive added value or tap into the team’s core skill set.  Many of these tasks fall into the realm of global regulatory affairs. Increased reporting demands from global regulatory bodies, coupled with internal pressures to maintain...
Read More
RickSax
To be successful in the dynamic environment of today’s healthcare industry, biopharmaceutical companies need to do two things:  Figure out how to harness disparate data sources from payers, providers, patients and their own vast data warehouses.   Participate in partnerships with payers, providers, and even other biopharma companies with the goal of crafting end-to-end solutions that help them all to be more successful.  These two strategies are the building blocks of a systems-oriented approach to healthcare. systems thinking looks at the end-to-end drug development process and leverages data from highly disparate sources to make better, faster decisions throughout the development lifecycle.  These partnerships can’t just occur in the final stages of...
Read More
BrianKelly
A systems-thinking approach to drug discovery, development and delivery, will help biopharmaceutical companies gain efficiencies in their process, and demonstrate the value proposition of their products that payers now demand. But the success of this model is predicated on their ability to access integrated healthcare data. There are six sets of data that the healthcare industry needs to take care of any individual patient --    Clinical data, which increasingly resides in electronic medical records.   Economic data to demonstrate the financial proposition of a treatment –which is often defined as quality divided by cost.   Patient-reported outcome data, including things like side effects, how well patients feel when they’re on medications, and whether they...
Read More
DeanSummerfield
One of the added complexities around defining the value of a treatment option is that it is dependent on the therapeutic category and the disease one is trying to address. Because of population size, current demand, and proven profitability of competing products, the value of some treatment categories are far easier to quantify than others. In our recent report , we asked stakeholders how easy or difficult it is to quantify the value of different treatment categories. Here’s what we found out.  Everyone agrees that Alzheimer’s is a difficult category to quantify. There was an almost unanimous agreement that defining the value of treatments for Alzheimer’s is very difficult to do, which makes sense. There are currently no products or available treatments to give long-term...
Read More
John Doyle
Some people assume that finding treatments for rare diseases offers little economic incentive for biopharmaceutical companies. If these diseases are so rare, the argument goes, who is going to buy the product. But that is a misconception. Research into rare disease treatment can be quite lucrative. They actually have a large potential market size with high market growth rate compared with the overall prescription drug market. And the severity of unmet need and general lack of competition in these categories leave potential to charge a premium making rare disease treatments are an attractive option for biopharma.  Consider the facts:  1. Roughly 30 million people in the US and another 30 million people in the EU suffer from rare diseases. Even with more than 400 products on the...
Read More
RobinHuff
As the incidence of diabetes continues to rise, more and more children are being affected by this life-changing chronic condition. Research from the International Diabetes Foundation shows that 78,000 children develop type 1 diabetes every year, and the incidence of type 2 diabetes in the pediatric population is also on the rise, with type 2 now accounting for more than 10% of newly-diagnosed diabetes in children between the ages of 12 and 16 years. Moreover, at 18 years of age the incidence of type 1 and type 2 diabetes is nearly identical. Despite the growing demand for treatment options, there is currently an unmet need for innovative, safe therapies to treat type 2 diabetes in the pediatric population. Many compounds have recently been approved or are in late-stage...
Read More
PatrickJordan
A year after producing the first Model T and with an eye to improve productivity, Henry Ford famously told his management team that “Any customer can have a car painted any color that he wants so long as it is black.” Nobody liked the idea. After selling 10,607 Model T’s the previous year, which was more than any manufacturer had ever sold, the company’s sales people thought even greater sales could be achieved with more models. Ford disagreed and said they were too preoccupied with the 5% of those with special wants, not the 95% of buyers. It was this line of thinking — addressing the needs of the largest segment of buyers and standardizing production — that took the cost of Model T from $950 in 1908 to $300 in 1924.  Standardization plays a critical role in healthcare. In...
Read More
EricaCaveney
Diabetes is a major global health issue that affects millions of people worldwide. And trends suggest that is only going to get worse. Consider these facts: In 2011, 366 million people had diabetes. That number is projected to rise to 592 million by 2035, according to the International Diabetes Foundation (IDF).  Diabetes caused 4.6 million deaths in 2011, according to the World Health Organization ( WHO ). It accounted for at least $465 billion in healthcare expenditures. This was approximately 11 percent of the total healthcare expenditures in adults age 20 to 79.   In the United States, diabetes affects 25.8 million people of all ages -- approximately 8.3% of the U.S. population, according to the American Diabetes Association (ADA)....
Read More
BrianKelly
One can debate many aspects of the U.S. Affordable Care Act (ACA), but there are two benefits to come out of the ACA that I’m particularly excited about.  The first is that it promises to expand access to healthcare insurance for a huge population of people that, up until now, never had it. That’s an amazing benefit to those uninsured individuals, and it will be a boon to the healthcare industry’s ability to gather more robust data about these populations.  As these people come into the system, we will be able to capture their healthcare information. That’s information we never had access to before they were paying customers. Over time, that will be a good thing for the industry as a whole.  The ACA will also support the trend of moving away from a pay-for-service model to a...
Read More
PatrickJordan
In the United States, the Affordable Care Act is pushing healthcare providers toward a pay-for-outcomes approach that promises to be an enormous challenge for already resources strapped hospitals across the country. A pay-for-outcomes approach requires hospitals to have mature data management infrastructure and skill sets so they can capture and analyze data about clinical results and use those results to shape the way they deliver care. Going forward, financial incentives will align around data integration, which means providers will need to demonstrate — through hard data — that patients are receiving the right care, in the right environment, and that their quality of life is improved.  But data management isn’t a core skill set for most care providers. They are focused on...
Read More